多种β-内酰胺类抗菌药物对耐氧亚氨基头孢菌素的大肠埃希菌和克雷伯菌属临床分离株的体外活性。
In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.
作者信息
Jett B D, Ritchie D J, Reichley R, Bailey T C, Sahm D F
机构信息
Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
出版信息
Antimicrob Agents Chemother. 1995 May;39(5):1187-90. doi: 10.1128/AAC.39.5.1187.
Abstract
Broth microdilution testing was used to study the activity of several beta-lactam antimicrobial agents, including piperacillin-tazobactam and cefepime, against 108 clinically derived Escherichia coli and Klebsiella sp. strains resistant to oxyimino cephalosporins (i.e., putative extended-spectrum beta-lactamase producers). On the basis of the percentage of susceptible strains, imipenem (100%), cefotetan (> or = 92%), and piperacillin-tazobactam (> or = 86%) were the most active agents. Cefepime activity (52 to 64% susceptible) was comparable to that of cefotaxime (40 to 63% susceptible) and aztreonam (20 to 63% susceptible). Among all beta-lactams tested, imipenem and cefotetan demonstrated the highest and most consistent level of activity and were the least affected by challenges with increased sizes of inocula of these resistant organisms.
摘要
采用肉汤微量稀释试验研究了几种β-内酰胺类抗菌药物，包括哌拉西林-他唑巴坦和头孢吡肟，对108株临床分离的对氧亚氨基头孢菌素耐药的大肠埃希菌和克雷伯菌属菌株（即假定的超广谱β-内酰胺酶产生菌）的活性。根据敏感菌株的百分比，亚胺培南（100%）、头孢替坦（≥92%）和哌拉西林-他唑巴坦（≥86%）是活性最强的药物。头孢吡肟的活性（52%至64%敏感）与头孢噻肟（40%至63%敏感）和氨曲南（20%至63%敏感）相当。在所有测试的β-内酰胺类药物中，亚胺培南和头孢替坦表现出最高且最一致的活性水平，并且受这些耐药菌接种量增加的影响最小。
相似文献
1
In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.
Antimicrob Agents Chemother. 1995 May;39(5):1187-90. doi: 10.1128/AAC.39.5.1187.
2
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
J Clin Microbiol. 1998 Sep;36(9):2575-9. doi: 10.1128/JCM.36.9.2575-2579.1998.
3
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.
Pharmacotherapy. 2003 Oct;23(10):1232-7. doi: 10.1592/phco.23.12.1232.32706.
4
5
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Diagn Microbiol Infect Dis. 2007 Mar;57(3):341-4. doi: 10.1016/j.diagmicrobio.2006.08.016. Epub 2006 Dec 1.
6
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x.
7
8
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Diagn Microbiol Infect Dis. 1998 Mar;30(3):215-28. doi: 10.1016/s0732-8893(97)00234-4.
9
Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Int J Antimicrob Agents. 2004 Dec;24(6):585-91. doi: 10.1016/j.ijantimicag.2004.08.008.
10
Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
BMC Infect Dis. 2017 Dec 18;17(1):776. doi: 10.1186/s12879-017-2873-z.
引用本文的文献
1
Changing Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North India.
Cureus. 2023 Mar 17;15(3):e36317. doi: 10.7759/cureus.36317. eCollection 2023 Mar.
2
Intense intestinal carriage and subsequent acquisition of multidrug-resistant enterobacteria in neonatal intensive care unit in Morocco.
PLoS One. 2021 Jun 30;16(6):e0251810. doi: 10.1371/journal.pone.0251810. eCollection 2021.
3
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034.
4
Antibiotic Susceptibility Pattern of ESβL Producing Klebsiella pneumoniae Isolated from Urine Samples of Pregnant Women in Karnataka.
J Clin Diagn Res. 2014 Oct;8(10):DC08-11. doi: 10.7860/JCDR/2014/9594.5048. Epub 2014 Oct 20.
5
Extended-spectrum β-lactamases in Gram Negative Bacteria.
J Glob Infect Dis. 2010 Sep;2(3):263-74. doi: 10.4103/0974-777X.68531.
6
Extended-spectrum beta-lactamases: a clinical update.
Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005.
7
Extended spectrum beta-lactamases in Eschericia coli isolated from community-acquired urinary tract infections in the Gaza Strip, Palestine.
Ann Saudi Med. 2004 Jan-Feb;24(1):55-7. doi: 10.5144/0256-4947.2004.55.
8
Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
J Clin Microbiol. 2004 Jan;42(1):269-75. doi: 10.1128/JCM.42.1.269-275.2004.
9
In vitro and in vivo activities of AM-112, a novel oxapenem.
Antimicrob Agents Chemother. 2003 May;47(5):1652-7. doi: 10.1128/AAC.47.5.1652-1657.2003.
10
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Antimicrob Agents Chemother. 2001 Dec;45(12):3548-54. doi: 10.1128/AAC.45.12.3548-3554.2001.
本文引用的文献
1
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
2
Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital.
J Clin Microbiol. 1993 Feb;31(2):179-84. doi: 10.1128/jcm.31.2.179-184.1993.
3
Cefepime: the next generation?
Clin Infect Dis. 1993 Sep;17(3):369-79.
4
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Antimicrob Agents Chemother. 1994 Feb;38(2):195-9. doi: 10.1128/AAC.38.2.195.
5
Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.
Antimicrob Agents Chemother. 1994 Jan;38(1):71-8. doi: 10.1128/AAC.38.1.71.
6
Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.
Ann Intern Med. 1993 Sep 1;119(5):353-8. doi: 10.7326/0003-4819-119-5-199309010-00001.
7
Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.
Antimicrob Agents Chemother. 1994 Apr;38(4):761-6. doi: 10.1128/AAC.38.4.761.
8
In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
Antimicrob Agents Chemother. 1994 Nov;38(11):2663-4. doi: 10.1128/AAC.38.11.2663.
9
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Drugs. 1994 Mar;47(3):506-35. doi: 10.2165/00003495-199447030-00008.
10
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.
Zotero 插件